ArticleOpen medicine (Warsaw, Poland)2026
6PPD-quinone exposure and Alzheimer's disease: insights from integrative network pharmacology, transcriptomics, machine learning, and molecular docking.
Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Computational Repurposing of Janus Kinase Inhibitors as Potential Therapeutic Candidates for Alzheimer's Disease.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To systematically investigate the molecular associations between 6PPD-quinone (6PPD-Q), an environmental transformation product of the tire antioxidant 6PPD, and Alzheimer's disease (AD) pathogenesis. Methods: An integrative strategy combining network pharmacology, transcriptomic validation, and machine learning was employed. Intersecting targets were identified through multi-database mining, followed by functional enrichment and protein-protein interaction (PPI) network analyses. Transcriptomic validation, SHAP-based XGBoost analysis, Mendelian randomization, and molecular docking were performed to evaluate target expression, diagnostic value, causal associations, and binding affinities. Results: A total of 92 intersecting targets were identified, enriched in synaptic structures, kinase activity, neuroinflammation, and apoptotic pathways. PPI analysis revealed 23 core targets, with Conclusions: This study provides the first systematic characterization of the molecular mechanisms by which 6PPD-Q may contribute to AD pathogenesis, potentially through inducing oxidative stress, activating neuroinflammation, and disrupting kinase signaling networks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.